Video

Our team behind the scenes at SXSW | Patient Stratification in Target ID, OMICS data

BenevolentAI develops AI models to help scientists better define underlying mechanisms of disease in very specific patients groups.

Looking at patient clinical and biomedical data we try to dig into molecular-level detail to redefine the disease and better endotyping for two main purposes: target identification and designing better clinical trials.

There is an abundance of patient data created e.g. electronic health records or genome sequencing. With increasing amounts of data being generated, we need AI models to help make meaningful discoveries.

Precision medicine is the future of medicine. Our belief is that by better understanding the underlying mechanisms of diseases in patients and identifying more specific and precise endotypes, we will be able to provide better medicines that are efficient in the specific patients groups they are developed for.

Watch Poojitha Ojamies, a Solutions Architect at BenevolentAI discuss how our team uses AI and machine learning to improve patient endotyping in multi-omics for target identification.  

More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022